key: cord-0929233-mddlhzvr
authors: Kuppalli, Krutika; Brett-Major, David M; Smith, Tara C
title: COVID-19 Vaccine Acceptance: We Need to Start Now
date: 2021-01-04
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa658
sha: a0db0621d8e7409ef2005903e67d02c8c56d93cf
doc_id: 929233
cord_uid: mddlhzvr

In this perspective, we discuss the importance of developing a vaccine to help curb transmission of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). The question remains: once a safe and effective vaccine is developed, will the public be willing to get it? We present information from one of the first tracking polls to assess public attitudes and perceptions towards a possible Coronavirus Disease 2019 (COVID-19) vaccine that suggests public hesitancy over a potential vaccine, concern regarding accelerating clinical trials, and unease over the vaccine approval process. Public health experts, government officials, advocates, and others in the scientific community should respect the signals of hesitancy and communicate sensitivity, applying lessons not only to how we message, but also in how we build this urgently needed vaccine if we are to have successful uptake once available.

M a n u s c r i p t 2 Abstract:

In this perspective, we discuss the importance of developing a vaccine to help curb transmission of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). The question remains: once a safe and effective vaccine is developed, will the public be willing to get it? We present information from one of the first tracking polls to assess public attitudes and perceptions towards a possible Coronavirus Disease 2019 (COVID-19) vaccine that suggests public hesitancy over a potential vaccine, concern regarding accelerating clinical trials, and unease over the vaccine approval process. Public health experts, government officials, advocates, and others in the scientific community should respect the signals of hesitancy and communicate sensitivity, applying lessons not only to how we message, but also in how we build this urgently needed vaccine if we are to have successful uptake once available.

Keywords: COVID-19, Vaccine, SARS-CoV-2, Public Health M a n u s c r i p t 3

Vaccines as a way to prevent infectious diseases such as polio, measles, tetanus, and pertussis have been one of the greatest scientific breakthroughs of the 20 th century leading to decreased morbidity, mortality, and outbreaks. 1 In the background of a global community struggling with how to improve vaccine acceptance we are now faced with the eruption and widespread devastation of a pandemic where the global scientific community is racing to develop an effective and safe medical countermeasure. The question remains: once an effective vaccine is developed, will the public be willing to get it?

While the pandemic may sway some previously undecided about vaccines, the development of the coronavirus vaccine along with its approval and distribution over the coming months and years will affect vaccine acceptance and uptake when eventually released. Additionally, this may have downstream consequences for future health emergencies. In short, we have a single shot to get this right.

While speed is clearly of the essence, we must work to ensure that risk communication and social mobilization around use of a novel vaccine match scientific evidence, and that a A c c e p t e d M a n u s c r i p t 4 skeptical public is appropriately briefed regarding this important countermeasure. Few in the public at large-or frankly among health professionals--understand systematic medical product development, let alone what terms such as -fast-tracked‖ mean in practical terms related to safety and efficacy of the vaccine product. The HPV vaccine was fast-tracked, and that fact remains a talking point for anti-vaccine groups who have exploited this same language for arguments against a COVID-19 vaccine as well. 3 Anti-vaccine narratives are not the only danger to a future COVID-19 vaccine. Social media has increasingly become a tool for spreading misinformation with groups exploiting antivaccine and anti-science sentiments and promoting conspiracy theories. 4 Additionally, concerns over government interference in the vaccine approval process has raised public concerns and serves to undermine the roll-out of a future COVID-19 vaccine. 4 We all should be anchored in science and prepared to address these factors along with vaccine hesitancy directly. When we are spending so much energy and resources to develop a vaccine it is equally essential we remain cognizant of the public concerns regarding safety that need to be addressed.

NBC LX/Morning Consult performed a tracking poll March 24-25 th that assessed attitudes and perceptions regarding a COVID-19 vaccine among a random sample of 2200 adults over 18 years of age (Table 1 : Demographics and Characteristics). 5 The respondents were 48% male and 52% female. Only 30% stated that they would be among the first to get vaccinated for COVID-19 once a vaccine is available, and 9% said they would not. Just shows that intent to get a COVID-19 vaccine has declined to 72% from May 2020 across all major political and demographic groups. 6 The decline in confidence is attributed to concerns that one will be approved before safety and efficacy is fully understood (77%) and the approval process will move too quickly without establishing appropriate safety and efficacy (78%). 6 A December survey, released as vaccination begins in healthcare workers, shows slight improvement, with 80% of individuals expecting to get the vaccine -eventually.‖ This moderate increase may be due to the fall surge in cases, as the percent of individuals concerned about infection was at the highest level since May. 7 That there has been such a significant falloff in public confidence over a COVID-19 vaccine amidst an ongoing pandemic is a signal that greater attention must be given towards communication and messaging with the public at large.

Factors that are critical when determining vaccine uptake include perceived safety, efficacy, and disease susceptibility. 1 Even if the specter of COVID-19 lingers, will that be enough for vaccine-hesitant individuals to accept the new vaccine for their children or themselves? Antivaccine physician Bob Sears has already suggested that COIVD-19 is -harmless‖ to anyone but the elderly and vulnerable groups, 8 

A c c e p t e d M a n u s c r i p t 6 Information Center (NVIC) suggests that COVID-19 vaccines may be the first -federal mandatory mass vaccinations‖. 9 These groups are sowing fear and suspicion before the vaccines are assessed; as such, the research behind them needs to be meticulous and communicated transparently to the public while trials are ongoing. Additionally, data thus far indicates most children with SARS-CoV-2 are asymptomatic or have mild disease, although some may develop multisystem inflammatory syndrome in children (MIS-C) after infection which can lead to significant cardiac complications. There is also growing data which indicates children may be a source of contagion and long-term morbidity from SARS-CoV-2 is still being understood. Given the evolving understanding of coronavirus disease in children, an honest conversation that includes discussion regarding a broad vaccination campaign for children will be important.

It is vital that governmental officials and public health experts understand that equally important to developing a safe and efficacious coronavirus vaccine will be the education, communication, and community engagement to help foster uptake of this important medical intervention if we are to stop the COVID-19 pandemic. It is vital that the scientific community communicate its understanding that the risk of a poor outcome from anything other than rigorous product development likely will reverberate throughout the community and potentially spill over into fear of other vaccines, with downstream repercussions for the management of pervasive threats and the next emerging disease. Speed is critical for this urgently needed vaccine, but ensuring it is safe is our ethical and humanistic responsibility, even if no one in the public is watching.

Conflict of Interest KK is a consultant for GalaxoSmikthKline but not related to vaccines. DBM and TS declare no potential conflicts.

This perspective does not include factors necessitating patient consent.

Vaccine rejection and hesitancy: A review and call to action. Open Forum Infect Dis

Combating vaccine hesitancy and other 21st century social determinants in the global fight against measles

Too Fast or Not Too Fast: The FDA's Approval of Merck's HPV Vaccine Gardasil

The online anti-vaccine movement in the age of COVID-19

Public Now Divided Over Whether To Get COVID-19 Vaccine. Pew Research Center

Americans prioritize frontline workers for coronavirus vaccine

A c c e p t e d M a n u s c r i p t 7 A c c e p t e d M a n u s c r i p t 8